NeuroLex EEG-Based ADHD Assessment Aid, Pivotal Study (NEBA)
This study has been completed.
Information provided by:
Lexicor Medical Technology, LLC
First received: January 7, 2008
Last updated: July 29, 2008
Last verified: July 2008
The study will evaluate the effectiveness of a standardized EEG method with the intended clinical users in the intended clinical settings with the intended population (patients who would typically receive a clinician's evaluation for ADHD). Multiple sites will be examined to provide a sample of patients across numerous communities with different demographics. The goal is to evaluate if the predictive accuracy of EEG will not be inferior to that of a widely-used and extensively validated ADHD scale in the prediction of ADHD in the intended use population as evaluated by Best Estimate Diagnosis.
Attention Deficit Disorder With Hyperactivity
||Observational Model: Cohort
Time Perspective: Prospective
||Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents
Primary Outcome Measures:
- 'Best Estimate Diagnosis' of ADHD applied in the intended population in settings with the intended users [ Time Frame: At prensentation to clinic with attention or behavior problems ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2008 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||6 Years to 18 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The study focuses on individuals who have consecutively presented to participating clinics with suspected attention and/or behavior concerns and would receive a clinician's comprehensive evaluation for ADHD. The study population includes male and female participants aged 6-17.99 years regardless of race, ethnicity, and socioeconomic origin. Because of inclusion of patients with consecutive presentation to provide a representative clinical sample, the exact numbers for sub-groups will not be controlled. The study population will include patients with comorbid conditions. The non-ADHD subgroup will include patients with other causes of attentional concerns, which may include other common psychiatric disorders, organic causes of attention problems (such as poor hearing, vision disturbances, remote head injury, substance abuse), and/or no diagnosis.
- Subject willing to voluntarily participate in a research study that includes EEG collection and analysis.
- Family/patient seeking comprehensive clinical evaluation for attention and/or behavior concerns.
- Male or female at least 6 years of age and who will not be over 17.99 years of age upon admission to study.
- Willing to stop any and all current psychiatric medications prior to or by entry into study.
- Subject and parent (or legal representative) of an educational level and degree of understanding sufficient to communicate suitably with the investigator, rater and study coordinator.
- Previous diagnosis of mental retardation. IQ < 70 by previous records.
- History of seizure disorder or of EEG abnormalities. On anticonvulsants for seizure control.
- Metal plate or metal device in the head.
- Suicide ideation or gesture and/or homicidal ideation or gesture.
- Concomitant medications during participation in a research study. No prescription or nonprescription medications with psychoactive properties that may affect EEG (such as over-the-counter dietary supplements, pseudoephedrine, or phenylpropanolamine). No antipsychotics, no psychostimulants, no antidepressants. Washout of at least one week or longer depending on the medication and clinician's judgment. Medication used for medical reasons must be cleared by research staff with consideration of known effects on EEG.
- Known serious medical problems (cardiovascular, hematological, liver, seizure disorder, renal, or chronic respiratory problems).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00595751
|Dothan, Alabama, United States, 36303 |
|Indian Crest Pediatrics
|Westminster, Colorado, United States, 80021 |
|Medical College of Georgia
|Augusta, Georgia, United States, 30912 |
|Mercer University School of Medicine
|Macon, Georgia, United States, 31207-0001 |
|New Orleans, Louisiana, United States, 70118 |
|Children's Specialized Hospital
|Toms River, New Jersey, United States, 08755 |
|SUNY Upstate Medical University
|Syracuse, New York, United States, 13210 |
|Rakesh Ranjan, MD & Associates
|Beachwood, Ohio, United States, 44122 |
|Eminence Research, LLC
|Oklahoma City, Oklahoma, United States, 73139 |
|Oklahoma University Child Study Center
|Oklahoma City, Oklahoma, United States, 73177 |
Lexicor Medical Technology, LLC
||Humberto Quintana, MD
||Steve Snyder, Ph.D.
||Lexicor Medical Technology, LLC
||Humberto Quintana, MD
No publications provided
||Howard Merry, President, Lexicor Medical Technology, LLC
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 7, 2008
||July 29, 2008
||United States: Institutional Review Board
Keywords provided by Lexicor Medical Technology, LLC:
ADHD, Attention Deficit Hyperactivity Disorder
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 11, 2013
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Signs and Symptoms